Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

379 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Therapeutic modulation of k-ras signaling in colorectal cancer.
Krens LL, Baas JM, Gelderblom H, Guchelaar HJ. Krens LL, et al. Among authors: guchelaar hj. Drug Discov Today. 2010 Jul;15(13-14):502-16. doi: 10.1016/j.drudis.2010.05.012. Epub 2010 Jun 2. Drug Discov Today. 2010. PMID: 20594936 Review.
The risk of cancer in users of statins.
Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. Graaf MR, et al. Among authors: guchelaar hj. J Clin Oncol. 2004 Jun 15;22(12):2388-94. doi: 10.1200/JCO.2004.02.027. J Clin Oncol. 2004. PMID: 15197200
Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer.
Graaf MR, Richel DJ, van Noorden CJ, Guchelaar HJ. Graaf MR, et al. Among authors: guchelaar hj. Cancer Treat Rev. 2004 Nov;30(7):609-41. doi: 10.1016/j.ctrv.2004.06.010. Cancer Treat Rev. 2004. PMID: 15531395 Review.
Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan.
van Erp NP, Baker SD, Zhao M, Rudek MA, Guchelaar HJ, Nortier JW, Sparreboom A, Gelderblom H. van Erp NP, et al. Among authors: guchelaar hj. Clin Cancer Res. 2005 Nov 1;11(21):7800-6. doi: 10.1158/1078-0432.CCR-05-1288. Clin Cancer Res. 2005. PMID: 16278402
Formulation, quality control and shelf life of the experimental cytostatic drug cyclopentenyl cytosine.
Schimmel K, Guchelaar HJ, van Kan E. Schimmel K, et al. Among authors: guchelaar hj. Drug Dev Ind Pharm. 2006 Apr;32(4):497-503. doi: 10.1080/03639040500529150. Drug Dev Ind Pharm. 2006. PMID: 16638688
Genetic markers of treatment response in rheumatoid arthritis.
Wesoly J, Wessels JA, Guchelaar HJ, Huizinga TW. Wesoly J, et al. Among authors: guchelaar hj. Curr Rheumatol Rep. 2006 Oct;8(5):369-77. doi: 10.1007/s11926-006-0068-5. Curr Rheumatol Rep. 2006. PMID: 16973111 Review.
Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease.
Kooloos WM, de Jong DJ, Huizinga TW, Guchelaar HJ. Kooloos WM, et al. Among authors: guchelaar hj. Drug Discov Today. 2007 Feb;12(3-4):125-31. doi: 10.1016/j.drudis.2006.11.013. Epub 2006 Dec 4. Drug Discov Today. 2007. PMID: 17275732 Review.
Preventing adverse drug events in hospital practice: an overview.
Rommers MK, Teepe-Twiss IM, Guchelaar HJ. Rommers MK, et al. Among authors: guchelaar hj. Pharmacoepidemiol Drug Saf. 2007 Oct;16(10):1129-35. doi: 10.1002/pds.1440. Pharmacoepidemiol Drug Saf. 2007. PMID: 17610221 Review.
Pharmacogenetics of EGFR and VEGF inhibition.
Pander J, Gelderblom H, Guchelaar HJ. Pander J, et al. Among authors: guchelaar hj. Drug Discov Today. 2007 Dec;12(23-24):1054-60. doi: 10.1016/j.drudis.2007.10.016. Epub 2007 Nov 26. Drug Discov Today. 2007. PMID: 18061885 Review.
Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib.
van Erp NP, Gelderblom H, Karlsson MO, Li J, Zhao M, Ouwerkerk J, Nortier JW, Guchelaar HJ, Baker SD, Sparreboom A. van Erp NP, et al. Among authors: guchelaar hj. Clin Cancer Res. 2007 Dec 15;13(24):7394-400. doi: 10.1158/1078-0432.CCR-07-0346. Clin Cancer Res. 2007. PMID: 18094422 Clinical Trial.
379 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback